Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499

PURPOSE: To test the hypothesis that consolidation therapy with yttrium-90 ((90)Y) –ibritumomab tiuxetan after brief initial therapy with four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated mantle-cell lymphoma would...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Smith, Mitchell R., Li, Hailun, Gordon, Leo, Gascoyne, Randy D., Paietta, Elisabeth, Forero-Torres, Andres, Kahl, Brad S., Advani, Ranjana, Hong, Fangxin, Horning, Sandra J.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732008/
https://ncbi.nlm.nih.gov/pubmed/22851557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.2444
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items